UK-based regenerative medicine firm Tissue Regenix reached a deal to acquire its San Antonio-based competitor CellRight Technologies for up to $30 million. The acquisition, which is being funded through a placement of $52 million worth of new shares, expands Tissue Regenix's orthopedics product offering and US presence, said company CEO Antony Odell.
Tissue Regenix reaches $30M deal to buy CellRight Technologies
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.